EVENTS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022
- A total of 17 pediatric patients were treated with STRO-002 on a compassionate use basis; eight patients achieved complete remission, of which seven patients were MRD negative - - Safety and efficacy profile in this patient population provides added confidence to...
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., November 23, 2022 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...
Jefferies London Healthcare Conference – Presentation
37th Annual Meeting Society for Immunotherapy of Cancer (SITC) 2022 – Abstracts
Abstract Number 1103 Half-life extended, conditionally active IFNa prodrug induces tumor-selective activation and potent antitumor response Abstract Number 1191 STRO-003 is a novel ROR1-targeted ADC for breast and lung cancer Abstract Number 1359...
Credit Suisse 31st Annual Healthcare Conference – Presentation
64th American Society of Hematology Annual Meeting and Exposition – Abstract
Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
--Results from compassionate use program highlight promising activity of STRO-002 in children with rare form of acute myeloid leukemia, that is highly refractory to all standard-of-care therapies-- SOUTH SAN FRANCISCO, Calif., November 3, 2022 – Sutro Biopharma, Inc....
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., November 2, 2022 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...
2022 Wells Fargo Healthcare Conference – Presentation
Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
SOUTH SAN FRANCISCO, Calif., September 1, 2022 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...